A study conducted in a disease model does not necessarily show an effect on the disease's defining impairment. The specific measured outcomes determine what can be concluded. Primary study
What was reported
Investigators tested Semax and Selank in rats with 6-OHDA-induced parkinsonism-like injury. Neither peptide changed the reported motor-activity measure in the elevated maze or passive defensive behavior. Selank reduced an anxiety-related measure in the maze. This was a behavioral animal experiment, not evidence of recovered motor function in patients with Parkinson’s disease. Primary report
Our appraisal: the model label cannot replace the endpoint
It would be misleading to summarize this as a general reversal of parkinsonism. The favorable finding concerned anxiety-related behavior, while the reported motor comparison remained neutral. Keeping both results visible prevents the disease name from making the result sound broader than it was.
Maze behavior also requires attention to how the outcome is constructed. Movement and exploration can affect anxiety-related measures, which is one reason separate activity observations are useful. A favorable behavioral interpretation is still bounded by the test conditions.
The comparison does not show that either peptide restored lost neurons or modified progressive human disease. Those claims require relevant tissue evidence, longitudinal outcomes, and eventually clinical testing. A toxin-induced lesion model is an experimental representation, not the entire condition.
Nor does testing two compounds in one study establish benefit from combining them. A head-to-head or parallel comparison of individual interventions is not a study of a blend. The distinction matters when findings are used to describe multi-ingredient products.
The study's contribution is narrower and clearer: an anxiety-related response to Selank was observed in this model despite neutral results on other reported behaviors. That is a research observation, not a treatment recommendation.
Frequently asked questions
Were rats used?
Yes.
Was the lesion model based on 6-OHDA?
Yes.
Did the reported motor-activity measure improve?
No.
Did passive defensive behavior change?
Not in the reported comparison.
Which peptide showed the highlighted anxiety-related effect?
Selank.
Does this prove neuron regeneration?
No.
Does studying both peptides validate a combined product?
No.